文献速递急性肾损伤慢性肾脏病

急性肾损伤后控制尿液浓缩以评估肾脏疾病进展生物标志物的考量

Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney Injury.
PubMed 文献 · Kidney Int Rep · 2022-04-06

该队列研究纳入1538例住院患者(769例急性肾损伤),评估尿液生物标志物与复合慢性肾脏病结局的关联。住院期间尿肌酐和尿渗透压与复合慢性肾脏病结局呈负相关。对尿肾损伤分子-1、白细胞介素-18和单核细胞趋化蛋白-1,经尿肌酐或尿渗透压标化或校正后关联显著增强,但对白蛋白、中性粒细胞明胶酶相关脂质运载蛋白和几丁质酶3样蛋白1无显著改善。

要点

  • 住院期间尿肌酐和尿渗透压与复合慢性肾脏病结局呈负相关。
  • 对尿肾损伤分子-1、白细胞介素-18和单核细胞趋化蛋白-1,经尿肌酐或尿渗透压标化或校正后与慢性肾脏病的关联和预测显著增强。
  • 对白蛋白、中性粒细胞明胶酶相关脂质运载蛋白和几丁质酶3样蛋白1,标化或校正尿肌酐或尿渗透压无显著改善。

核心结论

  • 住院期间尿肌酐和尿渗透压与慢性肾脏病的发生和进展呈负相关。
  • 仅对部分生物标志物,经尿肌酐或尿渗透压标化或校正可增强关联并改善对慢性肾脏病的预测。
  • 在研究和临床应用中,纳入尿液浓缩校正应针对每个生物标志物个体化处理。

研究设计与样本

  • 急性肾损伤评估、系列评估及后续后遗症研究是一项2009年至2015年间纳入住院患者(伴或不伴急性肾损伤)的队列研究。
  • 共纳入1538例参与者,其中769例(50%)有急性肾损伤,300例(19.5%)在中位随访4.7年时发生复合慢性肾脏病结局。
  • 采用Cox比例风险回归评估尿液生物标志物与复合慢性肾脏病结局的关联及预测(C统计量)。
  • 采用4种方法处理尿液浓缩:对尿肌酐和尿渗透压进行标化或校正。

主要发现

  • 住院期间尿肌酐和尿渗透压与复合慢性肾脏病结局呈负相关。
  • 在急性肾损伤患者中,对尿肾损伤分子-1、白细胞介素-18和单核细胞趋化蛋白-1,经尿肌酐或尿渗透压标化或校正后,与慢性肾脏病的关联和预测显著增强。
  • 对白蛋白、中性粒细胞明胶酶相关脂质运载蛋白和几丁质酶3样蛋白1,经尿肌酐或尿渗透压标化或校正后无显著改善。
  • 尿调节素与结局的负相关在经尿肌酐标化后显著减弱,但经尿肌酐校正后未减弱。

临床怎么用

  • 在研究和临床应用中,纳入尿液浓缩校正应针对每个生物标志物个体化处理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Biomarkers of acute kidney injury (AKI) are often indexed to urine creatinine (UCr) or urine osmolarity (UOsm) to control for urine concentration. We evaluated how these approaches affect the biomarker-outcome association in patients with AKI. METHODS: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Study was a cohort of hospitalized patients with and without AKI between 2009 and 2015. Using Cox proportional hazards regression, we assessed the associations and predictions (C-statistics) of urine biomarkers with a composite outcome of incident chronic kidney disease (CKD) and CKD progression. We used 4 approaches to account for urine concentration: indexing and adjusting for UCr and UOsm. RESULTS: Among 1538 participants, 769 (50%) had AKI and 300 (19.5%) developed composite CKD outcome at median follow-up of 4.7 years. UCr and UOsm during hospitalization were inversely associated with the composite CKD outcome. The associations and predictions with CKD were significantly strengthened after indexing or adjusting for UCr or UOsm for urine kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), and monocyte chemoattractant protein-1 (MCP-1) in patients with AKI. There was no significant improvement with indexing or adjusting UCr or UOsm for albumin, neutrophil gelatinase-associated lipocalin (NGAL), and chitinase 3-like 1 (YKL-40). Uromodulin's (UMOD) inverse association with the outcome was significantly blunted after indexing but not adjusting for UCr or UOsm. CONCLUSION: UCr and UOsm during hospitalization are inversely associated with development and progression of CKD. Indexing or adjusting for UCr or UOsm strengthened associations and improved predictions for CKD for only some biomarkers. Incorporating urinary concentration should be individualized for each biomarker in research and clinical applications.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Wen Y, Thiessen-Philbrook H, Moledina DG, et al. Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney Injury. Kidney Int Rep. 2022. PMID: 35812275. doi:10.1016/j.ekir.2022.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。